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p-Lactamase-mediated resistance t o  p-lactam antibiotics is a feature of great clinical significance. p-Lactamases are a 
diverse group of bacterial enzymes that vary in  their abilities t o  hydrolyze p-lactam antibiotics. p-Lactamases possess 
an active site containing either a serine moiety o r  a zinc atom; serine p-lactamases are currently of greater clinical 
prevalence. This review considers the  molecular classification o f  p-lactamases, the structure o f  the serine p-lactamase 
active site and the mechanisms by  which (3-lactamase production may  become derepressed. The spread o f  p-lactamases 
in  the clinical setting and some important structural mutations that have extended the hydrolysis profiles of serine 
p-lactamases are also discussed. 
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INTRODUCTION 
The number of (3-lactamases that have been charac- 
terized has risen dramatically since these enzymes were 
first classified in 1973 [I]. Functional aspects of 
($-lactamase activity were reviewed in 1989 by Bush, 
who then proposed a system of classification [2-41. A 
revised classification scheme published within the last 
year included more than double the number of differ- 
ent (3-lactamases compared to the 1989 scheme [5]. 
The Bush-Jacoby-Medeiros classification is based 
on a functional assessment of each (3-lactamase. It 
attempts to categorize these enzymes with respect to 
the efficiency with which they hydrolyze a range of 
different substrates and the extent to which they are 
inhibited by clavulanate [5]. Nevertheless, these different 
parameters show tremendous variability, and a simpler 
approach to ($-lactamase classification, proposed by 
Ambler [6], involves consideration of the nucleotide 
sequences coding for these enzymes. This approach is 
considered further here, and is useful when considering 
the evolution of two particular classes of ($-lactamase as 
defined by the molecular scheme: class A and class C. 
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The relationship between this evolution and the clinical 
use of newer (3-lactam antibiotics has been reviewed 
recently [7] .  
MOLECULAR CLASSIFICATION OF b-LACTAMASES 
There are two broad groups of p-lactamases: those that 
have a serine moiety at the active site and those that 
have an atom of zinc at the active site. The members 
of these two categories form the four classes of Ambler’s 
molecular classification scheme [6]. Currently, serine- 
based enzymes account for three molecular classes and 
the zinc-based enzymes a single category. The two 
most prevalent and most important classes to date are 
the serine-based class C and class A enzymes. 
The class A enzymes are primarily but not 
exclusively penicillinases and most are plasmid-deter- 
mined [5]. The class C (3-lactamases are also serine- 
based and are mainly chromosomally determined 
enzymes. They preferentially hydrolyze the cephalo- 
sporins and are present in almost all Gram-negative 
bacilli [8] .  An exception to this is Salmonella, in which 
the chromosome lacks the structural gene for a 
chromosomal class C (3-lactamase [9]. In many Gram- 
negative bacilli the class C p-lactamases are capable of 
conferring resistance. However, in others, such as 
Escherichia coli, their presence does not usually confer 
resistance [lo]. Class D p-lactamases are a small group 
of serine-based enzymes evolutionarily related to the 
class C p-lactamases [l I] and capable of rapid hydrolysis 
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of oxacillin [ 121. Class B is composed of the zinc-based 
(3-lactaniases, which are very different structurally from 
the serine-based enzymes [13-15]. 'These are of 
increasing significance as many possess carbapenemase 
activity. 
The majority of class C enzymes are inducible [S]. 
E. coli possesses ampC, ampD and amPC:, three of the 
four genes that are necessary for induction, but lacks 
the fourth, the ampR gene [16,17]. The function ofthe 
0-lactamase in E.  roli remains a mystery. The class A 
enzymes are constitutive in most species and inducible 
in a few species of lesser clinical significance [5]. There 
is now a great deal of information available concerning 
the tertiary structure of class A and class C enzymes. 
Examination of such data permits a greater appreciation 
of p-lactamase evolution. 
p-LACTAMASES: THE HYDROLYTIC PROCESS 
0-Lactamases are typically 100 times larger than their 
substrates: the enzymes have molecular masses of bet- 
ween 30 kDa and 40 kDa [S], whereas the (3-lactams 
themselves have molecular masses in the region of 
0.3 kDa. 
(3-Lactamases inactivate 0-lactam antibiotics via 
disruption of the 0-lactam ring [ l X ] .  The negatively 
charged o-xygen of the carbonyl group on the (3-lactani 
ring is attracted into the active site by the positively 
charged amine groups of serine-70 and alanine-237, 
resulting in the formation of an acyl-enzyme complex 
with the hydroxyl group of the serine moiety at  
the active site [19]. The following step, deacylation, 
involves the hydrolysis of the 0-lactani ring. The 
presence of an appropriately oriented water molecule 
permits regeneration of the enzyme and the release of 
a hydrolyzed 0-lactam that is microbiologically inactive 
This process involves a series of important binding 
interactions, including the binding of a series of 
hydroxyl groups with a variety of functional groups, 
usually amines, within this active site [19]. The 
(3-lactam substrate has to be held in place for the active 
site serine to lyse this arnide bond successfully. There- 
fore, the structure of the active site is of great 
importance. 
[111. 
STRUCTURE OF THE 0-LACTAMASE ACTIVE SITE 
The nucleotide sequences for all penicillin-binding 
proteins (PBPs) and all serine (3-lactamases from both 
class A and class C contain common regions [20] (see 
Figure 1A). AU possess a region (termed a motif) 
comprising a serine moiety, two other variable amino 
acids and a lysine moiety. Similarly, there are other 
motifs, the SDN motif and the KTG motif. These 
give rise to a series of hydrogen bonds between the 
positively charged amine groups and the negative 
hydroxyl groups. 
Figure 1 (A) Schematic showing the hydrogen bonding 
network and the anlino acid residues of the binding site 
motifs of a class A p-lactamase. Note the importance of 
residues El66 and N170 of the omega loop in positioning a 
water molecule close to S70. (B) Hydrogen bond 
interactions between the functional groups of a cephalo- 
sporin molecule and the side-chains of the amino acid 
residues of the active site. Note that the NH groups of S70 
and A237 hold the carbonyl of the p-lactam ring in the 
oxyanion pocket. The side-chains of S130 and T235 anchor 
one end of the molecule and those of N132 and A237 
anchor the other. Adapted from Ghuysen [19]. Reprinted 
from Clinical Infectious Diseases, 24 (Suppl l), Medeiros 
AA. Evolution and dissemination of P-lactamases 
accelerated by generations of p-lactam antibiotics, S19-45, 
0 1997 by University of Chicago. 
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Crystallographic studies provide structural evidence 
for the nature of the p-lactamase active site. The 
TEM-1 p-lactamase molecule possesses an a-helical 
domain and a p-sheet of five antiparallel strands 
surrounded by a-helices [21]. At the N-terminus ofthe 
a-helix, H2 is serine-70 of the active site, in the 
numbering system of Sutcliffe [22]. Pivotal to the 
hydrolytic capabilities of the P-lactamase is the oxy- 
anion pocket, located between the N-terminus of H2 
and the B3 edge of the p-sheet. This region contains 
two positively charged amine groups. These groups 
interact with the carbonyl of the p-lactam ring and thus 
bind the antibiotic molecule, placing the amide bond 
of the p-lactam ring and the hydroxyl group of the 
active site serine in close juxtaposition. 
Sections of the p-lactam molecule, apart from 
the carbonyl group of the p-lactam ring itself, play 
significant roles in the enzyme-substrate interaction 
[23]. A typical cephalosporin will be drawn to the 
active site of a TEM-1 p-lactamase by the powerful 
interaction between its negatively charged (3-lactam 
carbonyl and the positively charged amines of the 
oxyanion pocket [21] (see Figure ZB). However, other 
significant binding interactions hold the substrate at the 
correct orientation within the active site. A carboxyl 
group (at the C4 position in cephalosporins), or an 
analogous substituent, is present in most (3-lactam 
antibiotics, and forms hydrogen bonds with serine-130 
and threonine-235 [24,25]. 
Another feature common to the (3-lactam anti- 
biotics, except the carbapenems and the clavams, is 
the peptide bond that holds the R-group (at the C7 
position in cephalosporins). The positively charged 
amide and the negatively charged carbonyl enter into 
binding interactions with asparagine-132 and alanine- 
237, respectively [19]. 
These binding interactions permit the very precise 
positioning of the (j-lactam in relation to the water 
molecule responsible for hydrolysis of the (3-lactam- 
ring amide bond, thus making enzymes like the 
TEM-1 p-lactamase particularly efficient in hydro- 
lyzing p-lactam antibiotics [19]. 
The omega loop 
An important difference between the class A and class 
C p-lactamases is the presence of the omega loop in the 
class A enzymes. If a large p-lactam molecule with a 
rigid side-chain-such as cefiazidime or cefotaxime- 
attempts to fit into the active site of a TEM-1 
f5-lactamase, a portion of the structure known as the 
omega loop interferes with the orientation of the 
p-lactam’s side-chain, preventing a precise fit. The 
omega loop is present in all class A p-lactamases, 
including the TEM-1 P-lactamase. It constricts the size 
of the active site cavity and provides a steric barrier to 
larger p-lactam molecules [21,26]. Therefore, these 
molecules are resistant to inactivation by the TEM-1 
@-lac tarnase. 
Aside from obstructing the entry of cephalosporins 
with large R-groups, the omega loop is significant 
because the hydrogen bonds formed by glutamate-166, 
a moiety within the loop, are instrumental in orienting 
the P-lactam-hydrolyzing water molecule, such that it 
is poised to hydrolyze or deacylate a p-lactam molecule 
as soon as an acyl-enzyme complex is formed [27]. 
The absence of this omega loop in class C 
p-lactamases makes the active site cavity much larger 
and much less efficient overall, certainly in hydrolyzing 
the penicillins [23]. However, this renders such 
enzymes capable of hydrolyzing larger p-lactams such 
as ceftazidime [21]. Furthermore, class C p-lactamases 
possess no residue that is functionally analogous to 
arginine-244 of the class A enzymes. The absence of 
arginine-244 alters the orientation of a water molecule 
that attacks the non-(3-lactam ring of clavulanate or the 
penicillin sulfones. Ths renders class C enzymes non- 
susceptible to inhibition by these p-lactams [28]. 
P-LACTAMASES AND THE CLINICAL USE OF 
ANTIBIOTICS 
All (3-lactam antimicrobials are natural products or 
semisynthetic derivatives thereof. For this reason, the 
release of these compounds into the environment is 
partly responsible for the selection of many different 
types of (3-lactamases. The clinical use ofmany different 
(3-lactam derivatives has introduced a selective pressure 
promoting a corresponding diversification among 
p-lactamases in the hospital environment (Table 1) [7]. 
Until the early 1960s, penicillin G was the mainstay 
of p-lactam therapy, and correspondingly the only 
p-lactamase observed in the clinical situation was 
a staphylococcal penicillinase [29]. With the advent 
of penicillinase-resistant penicdhns such as methicdlin 
and broader-spectrum agents such as ampicfin, plasmids 
coding for 6-lactamases spread throughout Gram- 
negative bacik. These included TEM-1 and ultimately 
over 30 different plasmid-mediated p-lactamases [30]. 
Plasmids existed prior to the antibiotic era but did not 
appear to code for antibiotic resistance genes [31]. The 
presence of a selective pressure generated by the clinical 
use of antibiotics promoted the union of plasmids and 
resistance genes. This has led to the diversity of 
p-lactamases seen at present. Currently, the use of new 
p-lactams is perpetuating, indeed accelerating, this 
cycle [7]. 
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Table 1 Stages in the history of 0-lactamase development 
Period Antibiotics introduced p-L,actanusc response 
~~~ 
1940-60 Penicillin Staphylococci acquire p-lactamases 
1960-78 Broad-spectrum penicillins a n d  
early cephalosporin\ 
1978-95 Cephamycins, 
oxyiininoce~~halosporins, 
inonohactanis, carhapenenis, 
p-lactamase inhihitors 
Plasmids deterniining p-ldctarnase\ (e.g. TEM-I) 
disseminate among Gram-negative bacilli 
1978-Promoter mutations cause Klcbriclln o r y f o o r  
to hyperproduce its species-spccific c1.1~ A 
chromosonid fLlactamase 
1979-Regulator gene mutation\ cause enzyme 
hyperproduction in Etitcrohacteriaceae . ~ n d  
Prerrdonromu spp. that produce itlducihlc 
chroniosomal p-lactania\e 
1982-Mutations of the structural gene\ of the 
plasmid-detcrinined TEM, SHV and OXA 
fl-lactania\e, enhance their affinity for third- 
generation cephalosporins and inoiiobacta~~~s 
1982--Entrrtiburtt.r and Sprrntin spp. .qnirc nwcl 
chraniosomal genes that determine cia% A 
carbapeneinases 
quire genes that determine 
clas~ C p-lactanme? 
1988-1'la~mids drterniiiiing carhapenem- 
hydrolyzing metallo-p~lactaindse emerge in Japan 
10'11-TEM iiiut:uits have decreased affinity for 
clavulaiiatc md sulfone p-l.ictamaic inhihitors 
P-Lactamase hyperproduction 
In 1981, mutations in the 6-lactamase induction- 
regulating genes led to the hyperproduction of class C 
(3-lactamases by genera such as Enterobarter, Citrobacter, 
Motganella and Serratia [32]. Recently, Christine Jacobs, 
Jean-Marie Fri.re, and Steffan Normark elucidated the 
molecular mechanisms associated with the hyper- 
production of class C chromosomal 6-lactamases in 
Gram-negative bacteria [33] (Figure 2). Hyper- 
production is associated with the processes of cell wall 
synthesis and cellular division [37,38]. Lysis of cell wall 
peptidoglycan leads to the formation of N-acetyl- 
glucosamine-anhydro-N-acetylmuramic acid-L-alanyl- 
u-glutamyl-meso-diaminopimelic acid (GlcNAc- 
anhMurNAc-tripeptide). The gene ampG codes for a 
permease which selectively permits the entry of this 
oligomer into the bacterial cell. 
Inside the bacterial cell, an aminidase removes the 
GlcNAc residue, leaving the fragment anhMurNAc- 
tripeptide. An amidase encoded by the ampD gene then 
removes the tripeptide from the N-acetylmuramic acid. 
The tripeptide is recycled into new cell wall by linking 
to UDP-MurNAc to form UDP-MurNAc-tripeptide. 
In a final step, D-alanine-D-danine is added, yielding 
UDP-MurNAc-pentapeptide, a murein precursor that 
is transported to the periplasm to be incorporated into 
new cell wall. This latter oligomer can bind to and 
modify a protein, a transcriptional activator (AmpR), 
that induces expression of the (3-lactamase gene. When 
bound to the transcriptional activator, UDP-MurNAc- 
pentapeptide suppresses it, turning off production 
of AmpC (3-lactamase (Figure 2A). anhMurNAc- 
tripeptide, the breakdown product of the peptidoglycan 
cell wall, can counteract the suppressive effect of UDP- 
MurNAc-pentapeptide. Increased cell wall breakdown 
due to 6-lactam antibiotics or mutation of a m p D  leads 
to accumulation of anhMurNAc-tripeptide, which 
blocks the inactivator and triggers hyperproduction of 
AmpC f3-lactamase (Figure 2B). Implied in this 
mechanism is a tremendous association between 
production of the AmpC (3-lactaniase and the regula- 
tion of cell wall formation, although it is unclear 
whether or not this 6-lactamase has any direct function 
in terms of cell wall regulation. Hyperproduction of 
class C chromosomal 6-lactamase is a phenomenon of 
clinical importance: 6% of patients with bacteremia due 
to Enterobacter cloacae and treated with a third-genera- 
tion cephalosporin yielded a subsequent blood isolate 
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of the same strain, resistant to the antimicrobial used 
[391. 
T = GlcNAc-anhMurNAc-tripeptide 
I = tripeptide (L-Ala-D-Glu-rn-A2prn) 
7 UDP-MurNAc-pentapeptide (tnpeptide-o-Ala-0-Ala) (4 
Mureln cell wall .. , . Newly rorrnea undergoing lysis 
\ \penlapeptide \& 
\ \  , . - -  
Mureln cell wall 
Figure 2 A model for peptidoglycan recycling and 
P-lactamase induction in enterobacteria. Hydrolases in the 
periplasm cleave the peptidoglycan cell wall to form the 
degradation product, N-acetylglucosamine-anhydro- 
N-acetylmuramic acid-L-alanyl-D-glutamyl-meso- 
diaminopimelic acid F )  [34]. AmpG permease transports 
it into the cytoplasm where an aminidase cleaves off the 
GlcNAc yieldmg anhydro-MurNAc-tripeptide. An amidase 
encoded by ampD recognizes specifically substrate 
containing anhydromuramic acid and cleaves the bond 
between it and L-alanine, releasing the stem tripeptide, 
L-danlne-D-glUtamiC acid-m-Azpm (I). This tripeptide 
attaches to UDP-MurNAc which then accepts D-danine- 
D-danine to form UDP-MurNAc-pentapeptide ( 1 ). This 
murein precursor moves into the periplasm to form new 
peptidoglycan [33]. Under normal growth conditions, 1 
also suppresses the AmpR transcriptional activator, probably 
by binding to it. (A) However, when large amounts of T 
exist in the cytosol, due to murein breakdown caused by 
p-lactams or mutation of am@, the suppressive effect of 1 
is nullified. (B) Thus, by regulating the relative amounts of 
T and 1, ampD may control peptidoglycan composition 
[35,36]. The regulatory function of the AmpC P-lactamase, 
if any, is unknown. Adapted &om [33]. 
Mutations of piasmid-determined p-iactamases 
In 1983, mutations in the plasmid-borne genes for 
the SHV-1 P-lactamase led to an increased affinity for 
third-generation cephalosporins and monobactams [40]. 
These mutations have become widely disseminated in 
hospitals throughout the world, primarily in Klebriella 
spp. Such strains were subsequently responsible for 
major outbreaks of p-lactam-resistant infection 
[41, 421. 
At a molecular level in the TEM-1 P-lactamase, a 
single amino acid change from an arginine to a serine 
at the 164 position of the amino acid sequence has been 
shown to produce an extended-spectrum p-lactamase 
(ESBL), TEM-12 [21,26] (Figure 3A). This mutation 
reduces the steric hindrance of the omega loop with 
regard to the entry of third-generation cephalosporins 
such as ceftazidime. However, this is at the expense of 
hydrolytic efficiency; the omega loop is also instru- 
mental in the accurate orientation of water within the 
active site [23]. Loss of rigidity in the omega loop 
compromises this aspect of its functionality, resulting in 
a weak ESBL that confers only low levels of resistance 
to third-generation p-lactams [43]. For these reasons, 
TEM-12 is of only minor clinical significance com- 
pared to some other ESBLs. 
TEM-26, on the other hand, is an ESBL of greater 
efficiency. It has the same mutation as TEM-12 at 
position 164, reducing rigidity in the omega loop, but 
the glutamic acid at position 104 in TEM-1 and TEM- 
12 has been replaced with lysine (Figure 3B). This 
compensates for the loss in catalytic efficiency (arising 
from the reduction in rigidity of the omega loop) by 
enhancing the ability of TEM-26 to bind to its 
substrate. 
Mutations within the TEM-1 binding cavity are 
of great clinical significance, but the TEM enzymes 
are by no means the only P-lactamase hierarchy capable 
of such modification. Similar mutations have been 
observed with 0x11-1, PSE-2 and OXA-10 [44]. 
More recently, altered substrate specificity through 
mutation of the binding cavity in a class C p-lactamase 
was first described [45]. 
Following identification of this development, 
Enterobacter and Serratia with novel chromosomally 
mediated class A carbapenemases became evident in 
1986 [46,47]. Fortunately, class A carbapenemases have 
remained relatively uncommon since then. 
In 1988, plasmid-mediated class C p-lactamases 
similar to the chromosomal enzymes of E. cloacae and 
Citrobacter freundii were identified [48-501. Some 
isolates from patients with Klebriella infection were 
noted to possess a p-lactamase with a strong sequence 
homology to the E. cloacae class C P-lactamase. This 
conferred resistance to cefoxitin in addition to the 
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third-generation cephalosporins. There have been a 
number of reports of plasmid-mediated class C 
enzymes since 1988; some appear to be derived from 
C. freundi i ,  others from E. cloacae, and some from 
Pseudomonas spp. [7]. 
L169 
/ L169 
Figure 3 (A) Ceftazidime in the binding site of TEM-12 
(R164S). The broken line between El66 and N170 
represents a loosened, more flexible omega loop caused by 
the R164S mutation that weakens the bondmg between 
R164 and N179 across the neck of the loop (not shown in 
this dlagram). This provides more room for the bulky 
substituent of ceftazidime. Note that negatively charged 
side-chains of El04 and E240 repel the terrninal carboxyl 
of the substituent. (B) Ceftazidime in the binding site of 
During the early 199Os, TEM mutants occurred 
with greater resistance to inhibition by clavulanate 
and other (3-lactamase inhibitors [51-531. However, 
strains producing these enzymes are even more sus- 
ceptible to first-generation cephalosporins than strains 
producing TEM-1, and are therefore unlikely to 
represent a major clinical threat. 
In 1991, a plasmid-mediated class B p-lactaniase 
capable of imipenem hydrolysis was reported from a 
single strain of Pseudomonas aevuginosa in Japan [54]. This 
was a cause for great concern, as carbapenemase activity 
is most uncommon in clinical practice. Then, in 1994, 
a Serratia marcescens isolate expressing a novel chronio- 
soma1 class B carbapenemase (IMP-1) was described, 
again originating in Japan [55], and spread within 
several several hospitals [56]. In subsequent isolates of 
S. marcescens, the IMP-1 gene was carried by a n  
integron-like element on a transferable large plasniid 
[57]. The IMP-1 p-lactamase gene has also been found 
in clinical isolates of Alcaligenes xylosoxidnns, Arudaniorias 
put ida,  and Klebsiella pneumoniae [.%I. This has the 
potential to be a major problem in Japan. A charac- 
teristic ofJapanese clinical practice is the widespread use 
of imipenem/ cilastatin, and this may be implicated. 
CONCLUSIONS 
In summary, bacteria resist p-lactani antibiotics hy 
several means. These include increased (3-lactaniase 
production, a modified rate of passage of antibiotics 
across the outer membrane, beneficial mutations in the 
binding cavity of an existing (3-lactamase, and the 
recruitment of novel (3-lactamase genes. The capacity 
to resist the onslaught of p-lactams in the clinic is 
possibly associated with the fact that bacteria have been 
exposed to a wide range of environmental p-lactams 
for many millions of years. Therefore, the selective 
processes necessary for resistance may have previously 
occurred in the environment and merely await ex- 
trapolation to the clinic. An example of this is the 
detection of a carbapenemase, IMI-1, in clinical isolates 
prior to the widespread clinical use of iniipeneni. 
For reasons such as this, the clinical importance of 
infectious disease remains undiminished. The con- 
tinued search for new ($-lactams is essential to sustain 
clinical success in the treatment of infection. 
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